ABSTRACT
INTRODUCTION
Ischemic heart disease is due to disparity between the oxgen supply and the metabolic demand of the myocardiu m (1) . Reduction in coronary blood flow is related to progressive atherosclerosis (2) . Insulin-like growth factor I (IGF-I), which is a mitogenic peptide that circulates in p lasma, has endocrine effects in numerous target tissues. Most plasma IGF-I originates fro m the liver, its production is stimulated by growth hormone (GH) secretion, and IGF-I mediates many of the anabolic actions of GH (3) . In addition to its anabolic properties, it has been suggested that IGF-I plays an important role in the develop ment of cardiovascular diseases (CVDs) (4,5) . Subjects with low circulating IGF-I levels are at significantly higher risk of developing CVDs (6) . Because IGF-I is important for tissue repair and cell proliferation, it also involved in the pathogenesis of atherosclerosis (4) . Atherosclerosis is widely accepted as a chronic inflammatory disease initiated by different vascular and extravascular sources (7) . The inflammatory process is involved throughout the different stages of atherosclerosis. The vulnerability of an atherosclerotic plaque is related to the presence of inflammation since it plays a crucial role in d isruption of the fibrous cap, which is a majo r pathophysiological event for the development of the acute coronary syndromes, such as acute myocardial infarct ion (AMI) and unstable angina (UA) (8) .
The mult ifunctional cytokine tumour necrosis factor-alpha (TNF-α) plays a central part in the inflammatory cascade that is a key feature in atherosclerosis (9) . TNF-α levels correlate with progression of early carotid atherosclerosis and it is also a marker for recurrent coronary events after a previous myocardial infarct ion (10, 11, 12) . Moreover, Proinflammatory cytokines, such as interleukin (IL)-6 and TNF-α play important roles in coronary arterial diseases by regulating inflammat ion, cellu lar adhesion, production of growth factors (13& 10) . Iron is physiologically essential, but excess iron can also be a toxic and lead to the formation of a cascade of free radicals (14,15) . Iron was reported as an important factor in the process of atherosclerosis (16) . Also, high levels of body iron, high LDL-cholesterol and antioxidant deficiency are regarded as oxidative risk factors for ischemic heart diseases (17) . Association between serum iron levels and pathogenesis of ischemic heart diseases is controversial. Whereas most data show no association, some have raised the possibility of a causal role, wh ile others have suggested a protective effect of iron. Roles of seru m iron and its relation with cardioprotective IGF-1, p roinflamatory cyokines (TNF and IL-6) in patients with acute myocardial infarct ion and unstable angina are indistinctive.
The aim of this investigation was to verify the role of inflammatory process and IGF-1 in patients with AMI and UA as well as to investigate the relationship of circulating IL-6, TNFα, IGF-1 and lipid profile with serum iron in these patients population.
SUBJECTS & METHODS

Study populati on
This study was carried out throughout co-operation between departments of Physiology, Biochemistry and Internal Medicine in Assiut Faculty of Medicine. The study was approved by the Assiut University Ethics Co mmittee and every participant signed the informed consent before enrollment.
The research enrolled 36 male patients with acute coronary syndromes (18 patients with AMI of mean age 52±8 years, and 18 patients with UA of mean age 54±7 years) and 6 control male subjects (of mean age 50±10 years). All patients were recruited fro m the Cardiac Clinic unit of Internal Medicine in Assiut University Hospital.
The normal volunteers had normotension (blood pressure: systolic < 140 mm Hg and diastolic < 90 mm Hg), normal resting ECG with no past history or evidence of cardiovascular disease or diabetes mellitus. The present study did not include patients or control subjects with a history of neoplastic, hepatic, thyroid, infectious, autoimmune o r peripheral atherosclerotic disease, any surgical procedure in the preceding 6 months or under treatment with antiinflammatory and/or lipid lowering drugs.
Patients with AMI were defined as presence of typical prolonged chest pain accompanied by serial changes on the standard 12-lead electrocardiogram and significant (twofold mo re than the upper normal range) increase in markers of myocardial damage as creatine kinase (CK), lact ic dehydrogenase (LDH) or Troponine-T. Patients with UA were defined as anginal pain at rest occurring during the preceding 6 hours with transient significant ischemic ST-segment or T-wave changes or both, without significant increases in markers of myocardial damage (CK, LDH, Troponine T).
All patients were ad mitted to hospital with in 6 hours from the onset of chest pain. All patients underwent med ical treat ment with combination of standard medications, including nitrates, β-adrenergic blockers, calciu m antagonists, low mo lecular weight heparin and antiplatelet drugs such as aspirin and/or clopidogrel. AMI and UA Pat ients were randomized and selected according to their seru m iron into low, normal and high serum iron subdivision. Low serum iron levels were less than 38 μg/dl, normal serum iron levels were fro m 38 μg/dl to 158 μg/dl, and high serum iron levels were h igher than 158 μg/dl (18) . The prevalence of major risk factors and medications among the normal control subjects and the two groups of patients are shown in table 1. 
Laboratory measurements
• Blood sample (5 ml) was obtained fro m healthy controls and patients within 1 h of admission. The samples were taken slowly from an antecubital vein and were transferred to chilled sterile disposable tubes without anticoagulant. The disposable tubes were pro mptly centrifuged at 3000 r. p.m. for 20 min. at 4 °C within 1 h of drawing to separate serum then serum immediately stored at −70 °C until used.
• Seru m iron was measured by atomic absorption/flame, emission spectrophotometer (A-A630-O2) at wave length 2483 nm and lamp current 10 mA (19) .
• 
RESULTS
AMI and UA patients with low, normal or high serum iron revealed a strong evidence of inflammation and reduced cardioprotective agents. A summary of these results is shown in Figures 1-9 and Tab le1-2.
Results of demographic data:
Baseline characteristics of the cases and controls are shown in (table  1) . Risk factors (age, smoking, hypertension, and diabetes mellitus and increase body mass index above 25 kg /m 2 ) occurred more frequently among patients.
Results of measured laboratory parameters:
Relati on to serum iron: Estimation of serum iron (mg/ dl) showed significant reduction in both AMI and UA patients with low and normal seru m iron when co mpared with that of control value. However, it significantly increased in both patients groups with high serum iron as compared with that of control subjects. Whereas; there were nonsignificant differences in serum iron levels between AMI and UA patients either with low, normal or h igh serum iron. These results are summarized in table (2-a).
Relati on to Pro-inflammatory cytokines:
Both measured proinflammatory cytokines as serum IL-6 and TNF-α (pg/ ml) increased significantly (P <0.001) in AMI and UA patients with low, normal and high serum iron when compared with control mean value as shown in table (2-a).
AMI patients with low serum iron exhibited significant higher seru m levels of IL-6 (P <0.05) and TNF-α (P <0.01) when compared with UA patients with low serum iron. While, AMI patients with normal serum iron displayed significant decrease of IL-6 (P <0.01) and increase TNFα (P <0.05) as compared with UA patients with normal seru m iron. Furthermore, IL-6 decreased significantly (P <0.001) in AMI patients with high serum iron in co mparison to that of UA patients with high serum iron (table 2 -a).
Statistic analysis showed significant increase serum levels of IL-6 (P <0.001) and TNFα, (P <0.05 and P <0.001 respectively) in AMI patients with low serum iron in relation to that of AMI patients with normal or high serum iron (figure 1-a). While in UA patients either with low, normal or h igh serum iron, there were non-significant changes in the levels of IL-6 and TNFα.. A summary of these findings is shown in figure  (2-a) .
Relati on to IGF-1 : serum levels of IGF-1 (pg/ml) decreased significantly in AMI with low, normal and high serum iron and in UA patients with low and normal seru m iron when compared with control value. Although in UA patients with high serum iron it decreased insignificantly in relat ion to that of control as shown in table (2-a).
AMI patients with low serum iron exhibited significant (P <0.05) lower serum levels of IGF-1 when compared with UA patients with low serum iron. While AMI patients with normal iron or high serum iron showed nonsignificant changes in IGF-1 levels as compared with UA patients with normal or high serum iron ( table 2 -a) .
Moreover, IGF-1 significantly decreased (P <0.001 and P <0.01 respectively) in AMI patients with low serum iron in relation to that of AMI patients with normal and high serum iron (figure 1-b). Like wise, there was a significant reduction in the levels of IGF-1 (P <0.01) in UA patients with low serum iron in comparison to UA patients with normal or high seru m iron ( figure 1-b) .
Relati on to risky lipid profile: As comparable to the control subjects, assessment of risky lipids (cholesterol, triglyceride and LDL-C) and atherogenic index revealed significant increase in both patients groups (table 2 -b).
AMI patients with low serum iron showed significant higher LDL-C (P <0.01), cholesterol (P <0.001) and atherogenic index (P <0.01) but nonsignificant increase of triglyceride level when compared with UA patients with low serum iron (2-b). While AMI patients with normal or high serum iron displayed nonsignificant changes in the levels of risky lipids except (LDL-C) as comparable to that of UA patients with normal or h igh serum iron( table 2 -b).
There was a significant increase mean values of cholesterol, LDL-C and atherogenic index in AMI patients with low serum iron as comparable to that of AMI patients with normal o r high serum iron (figure 1-C). Meanwhile, LDL-C and triglyceride levels significantly (P <0.05) increased in UA patients with lo w serum iron in co mparable to UA patients of normal or h igh iron (figure 2-C).
Relati on to cardioprotecti ve lipi d pr ofile: Seru m HDL-C (mg/dl), cardioprotective lip id, d iminished significantly (P <0.001) in both patients groups versus control mean value as shown in table (2 -b).
AMI patients with low serum iron exhibited significant decrease serum levels of HDL-C (P <0.05) when compared with UA patients with lo w serum iron. However, there was nonsignificant change as regard HDL-C in AMI patients with normal or high serum iron when co mpared with that of UA patients (table 2 -b).
In addition, HDL-C significantly (P <0.01 and P <0.001 respectively) decreased in AMI patients with low serum iron as comparable to that of AMI patients with normal or high serum iron (figure 1-c). Also, in UA patients with low serum iron, there was a significant reduction in the levels of HDL-C (P <0.05) in comparison to UA patients with normal or high serum iron. A summary of these results is shown in figure (2-c) .
Correlation:
In AMI patients with high serum iron, there was a statistically significant positive correlation of serum iron with HDL-C and IGF-1 as well as significant negative correlation with IL-6, TNFα, cholesterol, LDL-C, triglyceride and atherogenic index (Fig.3 and 4) . Likewise, in AMI patients with low serum iron, similar significant correlations were proofed except triglyceride level (figure 5 and 6).
UA patients with low iron showed statistically positive correlation between serum iron and IGF-1 and HDL-C and negative correlation with TNFα, IL-6, atherogenic index and LDL-C (figure 7 and 8). As well, UA patients with high serum iron exh ibited significant negative correlations between serum iron with TNFα, IL-6, triglyceride and atherogenic index but non significant relations with other parameters (figure 9). All values represent means ± SE and were analyzed by A Student Newman-Keuls t-test. AMI: acute myocardial infarction, UA: unstable angina, IGF-1: insulin like growth factors -1, TNFα: tumor necrotic factor α, IL-6: interleuk in-6. HDL-C = high density lipoprotein cholesterol, LDL-C = low density lipoprotein cholesterol. Ns: non significant. * Showing comparison between all groups Vs. control (*= P <0.05, ** = P <0.01, ***= P <0.001). ¤ Showing comparison between AM I patients with low iron Vs. UA patients with low iron (¤ P <0.05,¤¤ P <0.01, ¤¤¤ P <0.001).
• Showing comparison between AM I patients with normal iron Vs. UA patients with normal iron (• =P <0.05, ••= P <0.01). Ö Showing comparison between AM I patients with high iron Vs. UA patients with high iron (Ö Ö Ö = P <0.001). All values represent means ± SE and were analyzed by A Student Newman-Keuls t-test. AM I: acute myocardial infarction, UA: unstable angina, IGF-1: insulin like growth factors -1, TNFα: tumor necrotic factor α, IL-6: interleuk in-6. HDL-C = high density lipoprotein cholesterol, LDL-C = low density lipoprotein cholesterol. Ns: non significant. * Showing comparison between all groups Vs. control (*= P <0.05, ** = P <0.01, ***= P <0.001). ¤ Showing comparison between AM I patients with low iron Vs. UA patients with low iron (¤ P <0.05,¤¤ P <0.01, ¤¤¤ P <0.001).
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• Showing comparison between AM I patients with normal iron Vs. UA patients with normal iron (• =P <0.05, ••= P <0.01). Ö Showing comparison between AM I patients with high iron Vs. UA patients with high iron (Ö Ö Ö = P <0.001). 
DISCUSSION
Whereas a large body of evidence exists to confirm the pathophysiological role of inflammat ion in atherosclerosis and in rupture of atherosclerotic plaques, minimal informations are available regarding its role in ischemic heart disease and the 'protective' and 'counterbalancing' role of IGF-1 in this cases. Also, iron is known as a physiologically essential agent, but the association between serum iron level and pathogenesis of ischemic heart diseases is controversial. Whereas most data show no association, some have raised the possibility of a causal role, wh ile others have suggested a protective effect of iron. Our knowledge about the association between serum iron and inflammatory markers (TNF-α and IL-6) and IGF-1 is still incomp lete. In this report, we hypothesized that inflammatory cytokines, IGF-1, serum lip id and iron may influence on pathogenesis of AMI and UA. To illustrate these influence and to test our hypothesis, we carried out this investigation. To accomplish our goals, we set up three subgroups of AMI and UA patients with low, normal or high seru m iron as well as control subjects. The serum levels of IL-6, TNF-α, IGF-1 in control subjects and patients with AMI and UA, as well as the potential correlations of these parameters with serum iron and lipids in different studied groups were estimated.
Serum Iron Serum Iron
The present study showed predominance of s moking, hypertension, diabetes, hypercholestremia and increase body mass index in both AMI and UA patients that coincide with previous investigators (25,26) . Both AMI and UA patients with low, normal or high serum iron were characterized by increasing pr o-i nflammatory cytokines as TNF-α and IL-6.
In this study, the elevated levels of inflammatory cytokines, TNF-α and IL-6, in AMI and UA goes in line with other previous studies (10,9,27&28) . The inflammatory process is involved throughout the different stages of atherosclerosis. The mechanis ms of actions and roles of TNF α in pathogenesis of AMI and UA are supported by several observations. TNF α plays a central part in the inflammatory cascade and correlates with the progression and recurrence of myocardial infarct ion (9,28) . In addition, the vulnerability of an atherosclerotic plaque is related to the presence of inflammat ion since it plays a vital role in disruption of the fibrous cap, which is a major pathophysiological event for the development of AMI and UA reported that pro-inflammatory cytokines produced by lymphocytes and macrophages, inhibit the collagen synthesis by smooth muscle cells, and enhance the expression of proteases (matrix metalloproteinases, MMPs) that lead to proteolytic destruction of connective tissue matrix in vulnerab le atherosclerotic plaques.
The association between TNF-α and ischemic heart d iseases are supported by many investigations. TNF-α is related to several common risk factors for ischemic heart diseases (25) . Smoking is a strong risk factor for the development of cardiovascular diseases and also contributes to variation of TNF-α protein levels in healthy subjects (31) . In addition, TNF-α is synthesized by adipocytes and increased adiposity (obesity) leads to raised levels of TNF-α (32,33) as well as elevated risk for cardiovascular diseases. So that, the increased levels of TNF-α seen in association with ischemic heart may be attributable to environmental stimuli of in flammatory processes (as smoking and obesity), or genetic variations that contribute to individual differences in TNF-α levels (25) . The elevated level of IL-6 in both AMI and UA patients in the current study and its role in ischemic heart disease coincide with the other studies (34, 35) . Interleukin-6 is the main regulators of the acute-phase response of inflammation, often acting in synergistic and cascade-like reactions and is capable of inducing the synthesis of the whole spectrum of acute-phase proteins (36) . It is produced by several different cell types such as fibroblasts, monocytes, macrophages, T and B ly mphocytes, endothelial cells and myocytes (37) . Furthermore, IL-6 protein and gene has been shown to be present in the human atherosclerotic vessel wall and is believed to play a role in the atherosclerotic process (38) and acute coronary disease such as AMI and UA (39,34,35) .
Insulin like growth factor-1 (IGF-1 ) decreased i n AMI and UA patients wi th low, normal or high serum iron.
In our study, the significant reduction of serum level of IGF-1 in both AMI and UA patients in relation to controls is in agreement with previous reports and suggests the cardioprotective role of IGF-1 in selected patients' populations. The association between IGF-1 and ischemic heart disease is studied by other investigators (40,26) . IGF-I has insulin-like metabolic effects and originates fro m the liver under stimulat ion of growth hormone (GH). It med iates many of the GH anabolic and growth actions (41) . IGF binding protein-3 (IGFBP-3) inhibits the bioactivity of IGF-I by sequestering IGF-I into a circulating reservoir, thereby reducing the free active fraction of IGF-I in the circulat ion. Therefore, decreased IGF-1 and increased IGFBP-3 were associated with increasing risk of developing ischemic heart disease (40) . Because IGF-1 is important for tissue repair and cell proliferation, it has been implicated in the pathogenesis of atherosclerosis (3) , progression of focal coronary atherosclerosis ( 42 ), ischemic heart diseases reported that absence of 192-and 194-bp alleles of the IGF-I pro moter was associated with declining IGF-1 production and increased risk of myocardial infarction. These special effects of IGF-1 may be attributed to its ability to regulate myocardial structure and function and promote cardiac muscle growth, differentiation, pro moting t issue remodeling and survival during myocardial ischemia (6) . One of the most important property of IGF-I is its ability to suppresses myocardial apoptosis and improves myocardial function (5&45) . IGF-I may also increase cardiac output and myocardial contractility, which may contribute to imp roved survival after a AMI (6) . Taken collectively, these findings imp ly important roles for IGF-1 in pathophysiology of ischemic heart diseases and decrease the incidence of these cases. Potential therapeutic and prophylactic situation of IGF-1 in these cases need further studies. Risky lipids (cholesterol, triglyceride, LDL-C) and atherogenic index i ncreased whereas cardio-protective lipid, HDL-C declined i n both AMI and UA patients.
Alteration of serum lipid profile (significant increase of cholesterol, triglyceride, LDL-C, atherogenic index and highly significant decrease, P <0.001, of HDL-C) in both AMI and UA patients evident in this report harmonizes with other investigations. High trig lyceride and low HDL-C, were at least as powerful a predictor of ischemic heart diseases (IHD) as isolated high LDL-C (53) . So, it seemed more meaningful to focus on the combined lipid profile, high TGlow HDL-C, as a risk factor of IHD than on high TG and low HDL-C as individual risk factors. Therefore, scientific efforts to prevent IHD should include intervention against high TG-low HDL-C, and not just against hypercholesterolemia. A significant increase of atherogenic index (Cholesterol/HDL-C rat io) in both AMI and UA patients in this study coincides with other studies. Isabelle Lemieu x et al., (2001) (54) reported that total cholesterol/HDL-C ratio may be associated with more substantial alterations in metabolic indices predictive of ischemic heart disease risk than variation in the LDL-C/HDL-C ratio. Th is may propose the possibility of using atherogenic index as an indicator for ischemic heart risk.
The current study indicates that increase in risky lipids and reduction of HDL-C were especially in AMI patients with low serum iron than AMI patients with normal or high serum iron or UA patients with lo w serum iron that is in agreement with other studies. The concentration of LDL-C was regarded as oxidative risk factors for ischemic heart diseases (17) . In addition, in AMI patients, both interleukin 10 and HDL-cholesterol decreased which confirmed their protective roles in coronary artery disease (55) . Controversy, Lee et al. (2006) (18) reported that serum TG and HDL-C were not change significantly in ischemic heart disease (IHD) patients with low, normal, or high serum iron, whereas LDL-C were increased in IHD patients with lo w serum iron, co mpared with the normal subjects. Collectively, we can propose that lipid profile is an important pathophysiological parameter associated with atherosclerotic inflammatory process take place in ischemic heart diseases.
In the existing work, a significant positive correlation between serum iron with cardi o protecti ve agents IGF-1 and HDL-C and a neg ati ve correlati on wi th IL-6, TNFα, cholesterol, LDL-C, triglyceride and atherogenic index was evi dent in AMI patients with high or low serum iron. Likewise, a positive correlation between serum iron with IGF-1 and HDL-C and negative correlation with TNFα, IL-6, atherogenic index and LDL-C were man ifested in this investigation among UA patients with low serum iron. However, UA patients with high serum iron exhib ited only significant negative correlation between serum iron with inflammatory cytokines (TNFα and IL-6), triglyceride and atherogenic index. These proofed correlations in this study concur with other investigators (56&18) . Besides, Tziakas et al., (2003) (55) reported a strong positive correlation between Interleukin 10 (IL-10) and HDLcholesterol in AMI patients, which might be an indication of a common synergistic anti-atherogenic action of two mo lecules in coronary artery disease.
These findings may propose that AMI and UA patients with low serum irons were associated with less cardiac protection and more proinflammatory states and risky lipids as well as may have a higher cardiovascular risk. In addition, Maria-Ch iara et al. (1997) (56) found that low serum iron levels were associated with an increased risk of ischemic heart disease and all-cause mortality. Also, high serum iron in both AMI and UA patients appeared to be associated with increasing cardioprotection and reducing proinflammatory cytokines and risky lip ids.
The association between low serum iron and risk of AMI and UA are supported by several observations. The role of reduced oxygenation due to decreasing hemoglobin and hematocrit on the myocardial performance has been proved, especially on the physiologic level, so that anemia is a known risk factor fo r ischemic heart disease (57) . When hemoglobin concentration is reduced to less than half the normal level, ventricular function is impaired, presumably because the coronary flo w has approached its maximu m (58) . Based on knowledge of the physiologic role of o xygen delivery to the myocardiu m, anemia may be a cause of more severe cardiovascular diseases as IHD, congestive heart failure, rhythm d isturbance and higher mortality rate (59) . Moreover, IHD patients with low serum iron appear to be associated with increased myocardial damage markers as lactic dehydrogenase and aspartate amino transferase suggesting that myocardial anaerobic metabolic activity may be higher in IHD patients with lo w iron (18) . Bilirubin, an antioxidant derived from b iliverdin (60) was significantly lower in the blood of IHD patients with low serum iron which suggest that bilirubin had a protective role in the cardiovascular events (61,62&18) . Iron is physiologically essential; contradictory, dietary intake o f iron elevates LDL-C that was regarded as oxidative risk factor and decreases plasma antio xidant levels (17) . In addition, excess iron can be a toxic and lead to the formation of a cascade of free radicals and lipid pero xidation (14,15) and accelerate the process of atherosclerosis (16) . This effect may be due to the ease with which iron is reversibly oxidized and reduced and thus able to participate in the generation of numerous powerful oxidant species (14) . AMI patients with especially low serum iron incorporated in this study revealed significant increase the measured proinflammatory cytokines (IL-6, TNF-α) as well as risky lip ids and significant decrease cardioprotective, HDL-C and IGF-1 as comparable to that of AMI patients with normal or high serum iron and UA patients with low serum iron. Whereas in UA patients with lo w serum iron, trig lyceride significantly increased and cardiopotective agents (IGF-1 and HDL-C) decreased significantly in co mparison with UA patients with normal or high iron. (63) who found that IHD patients with low serum iron were associated with a proinflammatory state, such as increased TNF-α, IL-6, and C-reactive protein and decreased cardiac protective factor, such as decreased IGF-I.
Subsequently, low serum iron in AMI patients selected in this study induced more injurious effects than UA patients. These effects may be consistent because measured serum ion levels were much reduced in AMI (50.9±4.8 mg/dl) than UA patients (52.12±5.6 mg/dl) which produced more damaging effects. Beside, these effects may be reasoned to more damage in AMI, similar to chronic inflammatory diseases, may be accompanied by a significant decrease of iron and total iron binding capacity, especially during the first 3 days (64) . In addition, potential mechanisms include direct damage of the vessels or an immunologic inflammatory response were especially in AMI patients. An increased uptake of iron in the reticulo-endothelial system for synthesis of ferritin may account for the lowered Fe level and iron saturation of tranferrin and TIBC in cases of AMI (65, 66) . Moreover, these findings could be the result of the intensity and the duration of the inflammatory stimulus, which characterize AMI, as well as perhaps being the consequence of the different patterns of immunological reactions and pathophysiological processes that underlie AMI cases.
Conclusions:
The outcomes of this study can be summarized as following: Both AMI and UA patients were associated with a pro-inflammatory state, such as increased TNF-α and IL-6, increased risky lip ids (cholesterol, triglyceride, LDL-C, atherogenic index) and decreased cardiac protective factors, such as IGF-1 and HDL-C. These findings support the pivotal role of inflammat ion in pathophysiology of both patients' population as well as the protective role of IGF-1 in ischemic heart disease. In addition, low seru m iron in both AMI and UA patients was associated with more pro inflammatory state and less cardiac protection than normal subjects or patients with either normal or high serum iron. However, the deleterious effects of low seru m iron were mo re in AMI than UA patients. Also, a positive correlation was evident between serum iron and cardioprotective agents, IGF-1 and HDL-C with negative correlation with proinflammatory cytokines and risky lip ids. The underlying mechanis ms of these effects are open for further investigations. Of course, further extensive studies are required to clarify the detailed mechanis m of lo w iron in heart diseases Clinical application:
For clin ical applicat ion, the low levels of serum iron adjoined with other cardiac risk factors might be used as a set of prognostic markers fo r predicting possible occurrence and recurrence of ischemic heart diseases or possible sudden death. We may further propose that IHD patients should regularly monitor their seru m iron. In addition, strong therapeutic and preventive approaches of anemia and low serum iron might improve the outcome of IHD.
